

# Technical Information

## Vanin-1 mouse/rat

Cat. No.:	BI-VAN1MR
Tests:	96
Method:	<b>ELISA</b>
Range:	0 – 200 pmol/l
LLOQ:	6.25 pmol/l (STD2 6.25 pmol/l)
Incubation time:	4 h / 30 min
Sample volume:	5 µl
Sample type:	Serum, plasma, urine
Sample preparation:	Centrifuge freshly collected blood as soon as possible Store centrifuged samples at -20°C for longer storage. Samples are stable up to 4 freeze and thaw cycles. Hemolyzed or lipemic samples may cause erroneous results.
Reference values:	Median mouse serum (n=5): 22 pmol/l Median mouse plasma (n=5): 24 pmol/l Median mouse urine (n=6): 21 pmol/l Median rat serum (n=7): 7 pmol/l Median rat plasma (n=8): 7 pmol/l
Species:	Mouse, rat

### Intended use:

Vanin- (VAN1) is a GPI-anchored glycoprotein of 513 amino acids consisting of a base domain and an enzymatic nitrilase domain (Boersma et al., 2014). The ectoenzyme catalyzes the hydrolysis of pantetheine to pantothenic acid (vitamin B5) and cyteamine and thus, is involved in the regulation of oxidative stress and inflammation (Maras et al., 1999). Vanin-1 has a broad tissue expression with the highest levels being observed in kidney tubular epithelial cells (Pitari et al., 2000). The GPI anchor of Vanin-1 can be cleaved by a yet unknown mechanism, resulting in Vanin-1 being shed into the extracellular space. Function: Vanin-1 is an epithelial ectoenzyme activating the conversion of pantetheine into pantothenic acid (vitamin B5) and cysteamine (Pitari et al., 2000). It has been suggested that the release of cysteamine by Vanin-1 promotes oxidative tissue damage and inflammation by inhibiting the activity of antioxidants like superoxide dismutase (SOD) and glutathione (GSH) (Hosohata et al., 2011; Saghaei et al., 2012).

Indeed, Vanin-1 knockout mice have elevated stores of GSH and are more resistant to oxidative injury induced by whole-body gamma irradiation (Berruyer et al., 2004). On the other hand, several reports indicate that Vanin-1 might also act as tissue sensor for oxidative stress. In mice, antioxidant response-like elements could be identified in the promotor region of Vanin-1, which enhance the expression of Vanin-1 in the presence of oxidative stress (Berruyer et al., 2004). Similarly, Vanin-1 expression was shown to be upregulated in a human proximal tubular cell line after exposure to organic solvents (Hosohata et al., 2011). After renal ischemia-reperfusion in rats, a model involving oxidative tissue damage, renal Vanin-1 expression was also found to be upregulated (Yoshida et al., 2002). The highest levels of Vanin-1 expression could be assigned to renal tubular epithelial cells, while no expression is detectable in glomeruli (Hosohata et al., 2011; Pitari et al., 2000). Hence, Vanin-1 released from renal cells could be detectable in urine. In a study aimed to identify biomarkers for renal tubular injury, Hosohata and colleagues could indeed show in a rat model of nephrotoxicant-induced injury that

Vanin-1 is upregulated in renal tubules earlier than other markers and shed into urine (Hosohata et al., 2011). Subsequent studies further verified the validity of Vanin-1 as an early biomarker of renal tubular damage in drug-induced acute kidney injury (Hosohata et al., 2012, 2016a), obstructive nephropathy (Washino et al., 2019) and hydronephrosis (Hosohata et al., 2018), diabetic nephropathy (Fugmann et al., 2011), renal injury in experimental colitis (Hosohata et al., 2014) and spontaneously hypertensive rats under high salt intake (Hosohata et al., 2016b; Washino et al., 2018). Of note, Vanin-1 seems to have superior predictive value for acute kidney injury than established markers KIM-1, NGAL, or NAG (Fugmann et al., 2011; Hosohata, 2016; Hosohata et al., 2011).

Intended applications:

- Acute kidney injury (Hosohata et al., 2016a)
- Diabetic nephropathy (Fugmann et al., 2011)
- Drug-induced acute kidney injury (Hosohata et al., 2016a)
- Hydronephrosis (Hosohata et al., 2018), obstructive nephropathy (Washino et al., 2019)

For further information please contact / Für weitere Informationen wenden Sie sich bitte an /  
Pour plus d'informations, veuillez contacter:

[www.tecomedical.com](http://www.tecomedical.com)



A EUROBIO SCIENTIFIC COMPANY

Switzerland / Headquarters  
**TECO medical AG**  
Gewerbstrasse 10  
4450 Sissach  
Phone +41 61 985 81 00  
Fax +41 61 985 81 09  
Mail [info@tecomedical.com](mailto:info@tecomedical.com)

Germany  
**TECO medical GmbH**  
Wasserbreite 57  
32257 Bünde  
Phone +49 52 23 985 99 99  
Fax +49 52 23 985 99 98  
Mail [info@tecomedical.com](mailto:info@tecomedical.com)

Benelux  
**TECO medical Benelux BV**  
Prins Willem-Alexanderlaan 301  
7311 SW Apeldoorn, The Netherlands  
Phone +31 30 307 87 30  
Fax +31 30 307 49 39  
Mail [benelux@tecomedical.com](mailto:benelux@tecomedical.com)

Austria  
**TECO medical AG**  
Phone 0800 20 40 66  
Fax 0800 20 40 55  
Mail [info@tecomedical.com](mailto:info@tecomedical.com)